Cowen Analyst Likes Intercept Pharmaceuticals, ACADIA Pharmaceuticals And Raptor Pharmaceutical

Speaking on

, Ritu Baral of Cowen and Company said that

is a buy. The company has received a breakthrough status by the FDA and it is about to start a phase 3 in the NASH program, said Baral. She added that we are going to see a filing for a lead program that has a potential to get approved by the FDA at the end of 2015 or early 2016. She likes

because of Parkinson's psychosis treatment, which has a billion plus market. It has a breakthrough status by the FDA and the company has been a topic in numerous acquisition discussions. Baral is bullish on

. The stock has been struggling recently because of the weak Q4, but Baral thinks that the catalyst for this stock will come in May when the data of pediatric NASH program gets released.